Personalis, Inc. Launches ImmunogenomicsID™ for Multidimensional Immuno-Oncology Biomarker Analysis as the Latest Enhancement to the ACE ImmunoID™ Platform
Menlo Park, CA — February 6, 2018 — Personalis, Inc., a provider of advanced genomic sequencing and analytics for immuno-oncology, today announced the launch of ImmunogenomicsID, a new component of the ACE ImmunoID™ Platform. The ACE ImmunoID Platform, which uses patented ACE Technology, combines leading genome-scale sequencing with analytics to enable broad tumor immunogenomic characterization.
ImmunogenomicsID combines DNA and RNA sequencing data to generate an immunogenomic profile of the tumor and its microenvironment. These analytics highlight critical areas of tumor biology such as the antigen presenting machinery (APM), human leukocyte antigens (HLA), checkpoint modulation, and tumor escape. This further extends the ACE ImmunoID Platform which already includes neoantigen discovery capabilities.
“Cancer Immunotherapy has the power to be truly transformational. At Personalis, we continue to innovate to help our customers accelerate the development of safe, effective, next-generation immunotherapies,” said Personalis CSO, Dr. Richard Chen. “We continue to expand the capabilities of our ACE ImmunoID platform as a comprehensive biomarker platform for immuno-oncology. ImmunogenomicsID provides a comprehensive view of the tumor and its microenvironment and is designed to aid in the identification of biomarkers and signatures that can impact patient response to cancer immunotherapies.”
Personalis will be attending the Immuno-Oncology 360° Conference from Feb 7-9, 2018, with Dr. Erin Newburn presenting a talk entitled “Elucidating Neoantigens and Tumor Immunogenomics: Key Challenges and Solutions.” Representatives will also be available to answer questions about the company’s immunogenomics and neoantigen identification capabilities.
About ACE™ Technology
Next-generation sequencing is increasingly used to support immuno-oncology studies. However, typical NGS cancer offerings fall short for immuno-oncology in a number of areas including gaps in gene coverage, narrow gene footprint, limited validation studies, and a lack of integrated RNA analysis. Personalis addresses these issues with proprietary Accuracy and Content Enhanced (ACE) technology which forms the foundation of ACE ImmunoID.
ACE Technology improves every individual step in the next-generation sequencing (NGS) process, from nucleic acid extraction, to library preparation and sequencing, to data analytics. This makes it possible to achieve augmented coverage of difficult-to-sequence genomic regions that are missed with the use of conventional sequencing techniques.
Personalis, Inc. (www.personalis.com) is a leading precision medicine company focused on advanced NGS-based services for immuno-oncology and cancer for clinical trials and translational research. Personalis also provides DNA and RNA sequencing and data analysis of human genomes.
The Personalis ACE Exome and Transcriptome technology is designed to obtain the most comprehensive and accurate tumor molecular profile and each tumor’s unique immune microenvironment for immuno-oncology applications. The company’s clinical laboratory is GCP compliant, CLIA licensed and CAP accredited. Personalis is differentiated by advanced sequencing assays, algorithms and content for neoantigen characterization, customer regulatory support, and more. Visit our website at www.personalis.com and follow @PersonalisInc.
Media Contact for Personalis: